The healthy ageing market is embracing the microbiome.
The prebiotics, probiotics and synbiotics segment is projected to reach a value of $44 million by 2027; growth is being driven by the recognition of dysbiosis (also known as microbiome imbalance) as one of the 12 key hallmarks of ageing.1,2
So far, in response, most supplement brands have developed formulations that replenish the bacterial strains that are commonly depleted with age.
But as access to health data expands and our understanding of the microbiome’s wider impacts deepens, we must ask: is simply replacing what's missing enough or can we go further and match microbial strategies to personal ageing journeys?
Sergi Audivert, cofounder at AB-BIOTICS, reports.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Nutraceutical Business Review.
Subscribe now Already a subscriber? Sign in here.